Further Evaluation: Middle-Aged Male with HTN, AION + Chronic CRAO

Step 1: Rule Out Giant Cell Arteritis (GCA) FIRST

• ESR and CRP - markedly elevated in GCA
• Platelets - often elevated in GCA
• Clinical review of systems: headache, scalp tenderness, jaw claudication, polymyalgia rheumatica symptoms, temporal artery tenderness
• If GCA is suspected: temporal artery biopsy + start high-dose systemic steroids without waiting for biopsy result

In a middle-aged male without GCA features, nonarteritic AION is the far more likely diagnosis. Nonarteritic AION differs from arteritic by: less severe vision loss, absence of premonitory amaurosis fugax, normal/low ESR, and a "disc at risk" (small cup-to-disc ratio <0.2) in the fellow eye.

Step 2: Cardiovascular / Embolic Source Workup

Carotid Artery

• Carotid duplex Doppler ultrasound - most important single test; Hollenhorst plaques (refractile yellow cholesterol emboli at bifurcations) in CRAO arise from ulcerated carotid atheromas; also look for stenosis

Cardiac

• ECG - atrial fibrillation (thromboembolic source), ischemic changes
• Echocardiography (2D echo with bubble study if indicated) - valvular disease (calcium emboli arise from cardiac valves), intracardiac thrombus, patent foramen ovale (PFO)
• Holter monitoring or ambulatory ECG - to detect paroxysmal AF

Neuroimaging

• MRI brain with DWI - CRAO is an embolic stroke equivalent; up to 25% of CRAO patients have concurrent silent cerebral infarcts; MRI also helps evaluate for posterior circulation lesions

Step 3: Blood Tests

If patient is younger (<50) or has atypical features, add:

• Hypercoagulable panel: Factor V Leiden, Protein C & S, Antithrombin III, prothrombin gene mutation, antiphospholipid antibodies (lupus anticoagulant, anti-cardiolipin, anti-beta2-glycoprotein I)
• Hyperhomocysteinemia (fasting homocysteine)
• ANA - collagen vascular disease (SLE, polyarteritis nodosa)
• Syphilis serology (RPR/VDRL + FTA-ABS) - rare but treatable
• Serum protein electrophoresis - paraproteinemia (multiple myeloma, Waldenstrom)
• Hemoglobin electrophoresis - sickle cell disease

Step 4: Ophthalmic Assessment

• OCT (Optical Coherence Tomography) - assess RNFL (retinal nerve fiber layer) thinning in AION; confirm retinal ischemia pattern in CRAO
• Fluorescein angiography (IVFA) - assess retinal perfusion, arterial filling delays in CRAO; disc leakage in AION
• Visual field testing (perimetry) - altitudinal defect (inferior > superior) is classic for NAION; assess contralateral eye for "disc at risk"
• Fellow eye evaluation - cup-to-disc ratio <0.2 in the fellow eye is a predisposing factor for NAION; this eye is also at risk for AION
• Neovascularization surveillance - up to 20% of CRAO develop NVI/NVD/NVA/NVE at 4-5 weeks; monitor closely
• IOP measurement - rule out acute glaucoma as a mimicker

Step 5: Neurology Referral

• Refer to a stroke neurologist - CRAO carries the same 90-day stroke risk as a TIA (~10-15%); the patient needs antiplatelet/anticoagulant therapy guided by etiology
• MRA or CTA of head and neck if carotid duplex shows significant stenosis (>50%) - to plan for carotid endarterectomy/stenting

Summary of Key Priorities

1. ESR/CRP urgently - rule out GCA
2. Stroke workup: MRI-DWI brain + carotid Doppler + cardiac echo + ECG
3. Metabolic panel: HbA1c, lipids, CBC, coagulation
4. Ophthalmology follow-up at 4 weeks for neovascularization surveillance (CRAO)
5. Hypercoagulable screen if no obvious etiology found
6. Neurology co-management for secondary stroke prevention

Clinical Significance of Trigeminal Neuralgia + Current Medications in This Patient

1. Diagnostic Link: Why TN + AION + CRAO May Not Be Coincidental

Shared Vascular Mechanism

• Hypertension accelerates arterial dolichoectasia, which enlarges and tortuosifies vessels - this increases neurovascular contact at the trigeminal root AND promotes atherosclerotic plaques in carotid/ophthalmic arteries
• Posterior circulation atheromatous disease (especially involving the basilar artery and SCA) can cause both TN (by compressing CN V) and branch/retinal artery occlusion
• The clinical triad of HTN + TN + ophthalmic ischemia should raise suspicion for posterior fossa/vertebrobasilar atherosclerosis as a unifying etiology

What This Means for Workup

• MRI/MRA of the brain and posterior fossa is already indicated for the TN; now it is even more important - look for:
  • Neurovascular compression of CN V (confirm classical TN vs. secondary)
  • Basilar/vertebral artery ectasia or atherosclerosis
  • Pontine lacunar infarct (which can cause secondary TN)
  • Demyelinating plaques (MS causing TN)
  • Posterior circulation territory ischemia

2. Drug-Related Considerations

A. Oxcarbazepine - Key Concerns

B. Amitriptyline - Key Concerns

C. Pregabalin - Relatively Safer, but Note:

3. Revised Workup Additions - Given the TN History

Neuroimaging (upgraded priority)

• High-resolution MRI posterior fossa + MRA (3T preferred):
  • CISS/FIESTA sequence to visualize neurovascular contact at CN V root entry zone
  • DWI to look for pontine lacunar infarct (which can mimic or cause TN)
  • MRA of vertebrobasilar system - assess for ectasia, stenosis, atherosclerosis
  • Rule out demyelinating plaques (secondary TN from MS) or CPA/skull base tumor

Laboratory (add to existing panel)

• Serum sodium - urgently (oxcarbazepine + possible diuretic)
• ECG with QTc - both oxcarbazepine and amitriptyline have cardiac sodium channel effects; assess for Brugada pattern
• Oxcarbazepine level - if available, to assess therapeutic range
• Review antihypertensive drug list - check if CCB (CYP3A4 substrate) is being used and whether BP is adequately controlled

Ophthalmology

• Gonioscopy/anterior segment OCT - rule out narrow angles given amitriptyline use
• IOP measurement - critical given anticholinergic mydriasis risk

4. Summary Table: Drug-Specific Risks to Flag

Key Takeaway

Optic Nerve Atrophy: What It Adds to This Clinical Picture

1. What Type of Atrophy Is This, and What Does It Tell You?

2. The Diagnostic Pivot: This Triad Should Make You Think of MS

• Optic atrophy (end-stage optic neuritis or AION)
• Trigeminal neuralgia (classical demyelinating TN)
• Middle-aged woman

Why this distinction matters enormously:

• NAION produces sectoral/inferior altitudinal pallor (corresponding to the visual field loss)
• Demyelinating optic neuritis produces predominantly temporal pallor of the disc (papillomacular bundle involvement)
• If the pallor is temporal, this points away from pure ischaemia and toward a demyelinating process
• Band atrophy (nasal + temporal pallor) suggests a chiasmal or optic tract lesion

3. Revised Differential Diagnosis - Now with Optic Atrophy Added

4. Additional Investigations Now Required

High Priority - Reclassify the Optic Atrophy First

• Inferior/sectoral pallor → supports AION
• Temporal pallor → supports prior optic neuritis (demyelinating)
• Band atrophy (binasal + temporal) → suggests chiasmal/tract lesion
• Waxy diffuse pallor with attenuated vessels → consecutive (CRAO-related)
• Disc appearance: flat vs raised margin → distinguishes primary from secondary

Investigations to Add

Drug-Related Consideration for Optic Atrophy

• Oxcarbazepine and amitriptyline very rarely cause toxic optic neuropathy, but this should be considered if no other explanation is found - they would produce bilateral temporal pallor
• Ethambutol-like toxic neuropathy pattern is not expected here, but the combination of multiple CNS-active drugs warrants awareness

5. The Revised Unifying Picture

1. Hypertension
2. AION + CRAO (ischaemic)
3. Optic nerve atrophy
4. Trigeminal neuralgia